1,2,3 prior line of therapy, Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), Bortezomib+Dexamethasone (Vd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
1,2,3 prior line of therapy, Nuclear Export Inhibitor, Selinexor+Bortezomib+Dexamethasone (SVd), Bortezomib+Dexamethasone (Vd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is BOSTON, Study ID is NCT03110562